Power drug discovery with mRNA — the missing link in precision oncology.
Most precision oncology pipelines rely on DNA sequencing and digital pathology — and miss whether a mutation is actually driving biological activity. Wren’s proprietary mRNA liquid biopsy platform fills that gap.
See which mutations are biologically active.
Wren delivers real-time insights into gene expression, signal-pathway activity and tumor dynamics. Integrating our mRNA technology into your drug discovery lets you:
- Identify mutations that are biologically active — not just present
- Predict therapeutic efficacy and safety with greater clarity
- Accelerate development of targeted diagnostics and treatments
Why partner with Wren?
≥ 10 days at ambient temperature
Exclusive sample stabilization technology preserves whole-blood and saliva mRNA.
Just 0.2 mL of blood per test
Ultra-low volume requirements.
Results in as little as 3–5 days
For prospective studies.
Proven across the globe.
Over 115 national and international patents and 60+ clinical validation studies involving 70+ investigators from 45 leading medical institutions.
Current challenges in oncology drug development.
Communication gaps
Misalignments between the pharmaceutical and diagnostic industries lead to inefficiencies.
Focus on DNA & proteomics
Advances in NGS and digital pathology have largely overlooked mRNA gene-expression approaches.
Genomic analysis shortcomings
Analyses often miss insights by focusing on single mutations or broad datasets.
Transcription issues
The predictive power of DNA mutation profiling in cancer can be limited.
Liquid biopsy challenges
Most assays focus on single blood components, which do not capture the complete tumor status.
mRNA instability
The sensitivity of mRNA presents logistical challenges for accurate results.
Tissue sample limitations
Tumor heterogeneity and quality issues can make tissue data misrepresentative.
CRO performance
Many contract research organizations fall short of industry expectations.
Quality, efficiency and competitive pricing.
With extensive experience alongside local and global CROs, we deliver the pharma triad in biomarker and companion diagnostic (CDx) services.
Liquid biopsy specialization
Validated mRNA multi-gene expression assays used in 60+ clinical studies with more than 70 key opinion leaders worldwide.
Comprehensive analysis
mRNA from whole blood captures signals from cfRNA, exosomes and circulating tumor cells for a fuller picture of tumor content and immune response.
Analytical robustness
PCR-based assays over 100× more sensitive than RNA-Seq, using carefully selected gene panels.
Logistics made easy
Proprietary stabilization tubes keep RNA viable ≥10 days at room temperature and up to 6 years at −80 °C — from just 0.2 mL of blood or saliva.
Data outputs — straightforward and customizable
Binary readout. Positive/negative results on clinically validated cutoffs — ideal for patient selection.
Monitoring scores. Changes in ML numerical scores to track MRD or recurrence.
Raw data. Raw PCR data provided to enable sub-panel analyses.
Visualization. Gene clustering, heatmaps, volcano plots and more.
Regulated, research-use and custom.
Regulated blood mRNA assays
- NETest® — detects neuroendocrine differentiation in solid tumors (lung, prostate, colon).
- PROSTest® — designed for prostate cancer.
RUO assays
- Saliva assays for NET and prostate cancer.
- Whole-blood and saliva assays for lung, pancreas, colorectal, breast, melanoma and multiple myeloma.
Tailored gene panels
Custom mRNA gene panels for oncology, immunology and more — validated in 8–10 weeks.
From discovery to companion diagnostics.
Discovery & translational research
Biomarker/target discovery with our gene signatures and analytics.
POC, POM and PD — regulated biomarkers as efficacy endpoints; RUO assays for exploratory studies.
Patient monitoring
MRD detection — minimal residual disease or recurrence in oncology trials.
Early detection — monitor NET development in non-oncology trials with potentially carcinogenic drugs.
Patient selection & stratification
LDTs for early-phase trial patient selection.
Regulated IUO support for companion diagnostic (CDx) development.
Every sample matters.
Blood collection tubes
RNA stabilization tubes keep mRNA stable for at least 10 days — global ambient shipping.
Dedicated project management
We track every kit and shipment, with an experienced project manager on each study.
No preanalytical work
Extracting just 0.2 mL of whole blood avoids sample processing and its variability.
Quick turnaround
Real-time analysis for prospective studies; custom assays validated in 8–10 weeks.
Compliance & regulatory support
Our quality management system implements best-practice QC/QA for reliable results. As a CLIA-certified, CAP-accredited, NYSDOH-licensed and ISO 15189-certified laboratory, we support clients with reviews of the biomarker sections of INDs and study protocols, and participate in regulatory meetings.
Two cancers that intersect.
NETs and prostate cancer meet through neuroendocrine differentiation in prostate adenocarcinoma. Prolonged androgen deprivation therapy can induce it — producing a more aggressive, treatment-resistant cancer with a poor prognosis.
Neuroendocrine prostate cancer (NEPC) occurs in 30–40% of castration-treated prostate cancer cases and typically requires a tissue biopsy with immunohistochemical staining to diagnose. PET imaging with specific tracers may also help identify neuroendocrine lesions.
There is a significant unmet need for a reliable liquid biopsy to detect neuroendocrine differentiation caused by long-term hormonal therapy. Using NETest® alongside PROSTest® can address these needs — enhancing diagnostic, prognostic and therapeutic approaches for advanced, treatment-resistant prostate cancer.
Contact us to request a proposal
Tell us about your program — our team will scope assays, logistics and data deliverables.